158 related articles for article (PubMed ID: 34588898)
1. Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors.
Mozaffari Nejad AS; Fotouhi F; Mehrbod P; Alikhani MY
Saudi J Biol Sci; 2021 Oct; 28(10):5833-5840. PubMed ID: 34588898
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways.
Mozaffari Nejad AS; Fotouhi F; Mehrbod P; Keshavarz M; Alikhani MY; Ghaemi A
Microb Pathog; 2020 Oct; 147():104438. PubMed ID: 32777353
[TBL] [Abstract][Full Text] [Related]
3. Non-replicating Newcastle Disease Virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression.
Mohebbi A; Ebrahimzadeh MS; Baghban Rahimi S; Saeidi M; Tabarraei A; Mohebbi SR; Shirian S; Gorji A; Ghaemi A
Virus Res; 2019 Feb; 261():72-80. PubMed ID: 30599161
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis.
Keshavarz M; Nejad ASM; Esghaei M; Bokharaei-Salim F; Dianat-Moghadam H; Keyvani H; Ghaemi A
Saudi J Biol Sci; 2020 Jan; 27(1):47-52. PubMed ID: 31889816
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.
Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A
Virol J; 2020 May; 17(1):64. PubMed ID: 32370750
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
7. Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade.
Miri SM; Ebrahimzadeh MS; Abdolalipour E; Yazdi M; Hosseini Ravandi H; Ghaemi A
Cancer Cell Int; 2020; 20():380. PubMed ID: 32782438
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
Zamarin D; Martínez-Sobrido L; Kelly K; Mansour M; Sheng G; Vigil A; García-Sastre A; Palese P; Fong Y
Mol Ther; 2009 Apr; 17(4):697-706. PubMed ID: 19209145
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients.
Bai L; Koopmann J; Fiola C; Fournier P; Schirrmacher V
Int J Oncol; 2002 Oct; 21(4):685-94. PubMed ID: 12239606
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo.
Toyoda H; Wimmer E; Cello J
Int J Oncol; 2011 Jan; 38(1):81-7. PubMed ID: 21109928
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[
